Dr. Borgen on Advancements With HER2+ Breast Cancer

Patrick Borgen, MD
Published: Thursday, Nov 16, 2017



Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses advancements in the treatment landscape of HER2-positive breast cancer.

The view of HER2-positive breast cancer has changed, explains Borgen. Previously, HER2-positive breast cancer was thought to be the worst result a biopsy could detect, but targeted treatments have since revolutionized outcomes.
 


Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses advancements in the treatment landscape of HER2-positive breast cancer.

The view of HER2-positive breast cancer has changed, explains Borgen. Previously, HER2-positive breast cancer was thought to be the worst result a biopsy could detect, but targeted treatments have since revolutionized outcomes.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x